Erasca, Inc. Cash and Cash Equivalents
Erasca, Inc. (ERAS) had Cash and Cash Equivalents of $42.54 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-11
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $42.54M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $47.26M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $73.81M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $70.23M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $42.54M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $47.26M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $73.81M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $70.23M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $66.14M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $70.48M 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $67.74M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $68.89M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $172.80M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $172.80M 10-Q · filed 2025-08-12 | $76.73M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $93.08M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $112.86M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $138.79M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $272.76M 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $284.22M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $219.26M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $219.26M 10-Q · filed 2023-11-09 | $298.01M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $333.35M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $360.49M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $445.81M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $156.40M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $169.99M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $65.38M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $62.02M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $104.34M 10-Q · filed 2021-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |